Get started
Author

Marcella Martignoni

Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction
2006 · Marcella Martignoni, Geny M M Groothuis, et al. · Expert Opinion on Drug Metabolism & Toxicology · 1,521
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
2018 · Toni K Choueiri, James Larkin, et al. · The Lancet Oncology · 263
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
2015 · Andrea Sartore-Bianchi, Elena Ardini, et al. · JNCI Journal of the National Cancer Institute · 247
PDF
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
2025 · Mario Campone, Michelino De Laurentiis, et al. · New England Journal of Medicine · 193
Comparison of Mouse and Rat Cytochrome P450-mediated Metabolism in Liver and Intestine
2006 · Marcella Martignoni, Geny Groothuis, et al. · Drug Metabolism and Disposition · 102
PDF
An in vivo and in vitro comparison of CYP induction in rat liver and intestine using slices and quantitative RT-PCR
2004 · Marcella Martignoni, Ruben de Kanter, et al. · Chemico-Biological Interactions · 64
Chapter 13 Enantioselective recognition of two anticonvulsants, FCE 26743 and FCE 28073, by MAO, and relationship between MAO-B inhibition and FCE 26743 concentrations in rat brain
1995 · M. Strolin Benedetti, P. Tocchetti, et al. · Progress in brain research · 61
A new technique for preparing precision-cut slices from small intestine and colon for drug biotransformation studies
2004 · Ruben de Kanter, Annemarie Tuin, et al. · Journal of Pharmacological and Toxicological Methods · 57
Alka-372-001: First-in-human, phase I study of entrectinib – an oral pan-trk, ROS1, and ALK inhibitor – in patients with advanced solid tumors with relevant molecular alterations.
2015 · Filippo G. De Braud, Monica Niger, et al. · Journal of Clinical Oncology · 53
First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.
2017 · Toni K. Choueiri, James M. G. Larkin, et al. · Journal of Clinical Oncology · 39
Phase I and phase II metabolic activities are retained in liver slices from mouse, rat, dog, monkey and human after cryopreservation
2003 · Marcella Martignoni, Mario Monshouwer, et al. · Toxicology in Vitro · 37
Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.
2014 · Filippo G. De Braud, Lorenzo Pilla, et al. · Journal of Clinical Oncology · 32
An in vivo and in vitro comparison of CYP gene induction in mice using liver slices and quantitative RT-PCR
2005 · Marcella Martignoni, Ruben de Kanter, et al. · Toxicology in Vitro · 25
A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC).
2014 · Benjamin Besse, Marina Chiara Garassino, et al. · Journal of Clinical Oncology · 24
Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study.
2025 · Erika P. Hamilton, Michelino De Laurentiis, et al. · Journal of Clinical Oncology · 17
PDF
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial
2022 · James Larkin, Mototsugu Oya, et al. · The Oncologist · 16
Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma.
2016 · James M. G. Larkin, Michael S. Gordon, et al. · Journal of Clinical Oncology · 13
Lack of strain-related differences in drug metabolism and efflux transporter characteristics between CD-1 and athymic nude mice
2004 · Marcella Martignoni, Ruben de Kanter, et al. · Cancer Chemotherapy and Pharmacology · 13
Rxdx-101, an Oral Pan-Trk, Ros1, and Alk Inhibitor, in Patients with Advanced Solid Tumors with Relevant Molecular Alterations
2014 · F.G.M. De Braud, L. Pilla, et al. · Annals of Oncology · 9
PDF
Species and strain differences in drug metabolism in liver and intestine
2006 · Marcella Martignoni · University of Groningen research database (University of Groningen / Centre for Information Technology) · 8
Degradation of thymic humoral factor γ2 in human, rat and mouse blood: An experimental and theoretical study
2020 · Marcella Martignoni, Margherita Benedetti, et al. · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · 2
PDF
Abstract PD10-03: Subgroup analyses of VERITAC-2: A phase 3 trial of vepdegestrant, a PROTAC estrogen receptor (ER) degrader, versus fulvestrant in ER-positive/ human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC)
2026 · E. P. Hamilton, M. De Laurentiis, et al. · Clinical Cancer Research · 1
Phase II trial of nemorubicin hydrochloride (N) in combination with cisplatin (cDDP) administered by intra-hepatic artery (IHA) in patients (pts) with hepatocellular carcinoma (HCC): Final results.
2013 · Francesco Izzo, Thomas J. Vogl, et al. · Journal of Clinical Oncology · 1
Phase II trial of nemorubicin hydrocloride (nemorubicin) in combination with cisplatin (cDDP) in patients (pts) with hepatocellular carcinoma (HCC): First step results
2009 · F. Izzo, A. M. Catino, et al. · Journal of Clinical Oncology · 1
In vitro metabolism of THF-γ2 in human, Rat and mouse blood
1995 · R. Battaglia, M. Martignoni, et al. · Pharmacological Research · 1
Works count: 26
Citation count: 2,800
H-index: 16
I10-index: 18
Year
Topic
Type